Xiao-Bin Lv
Overview
Explore the profile of Xiao-Bin Lv including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
857
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang J, Luo X, Guo C, Dai Z, Tang X, Zhang F, et al.
BMC Cancer
. 2024 Nov;
24(1):1375.
PMID: 39523321
Background: Long non-coding RNA (lncRNA) plays a vital role in the occurrence and development of varieties of tumors. Previous studies have shown that lncRNA GClnc1 is highly expressed in osteosarcoma...
2.
Luo X, Zhang J, Guo C, Jiang N, Zhang F, Jiao Q, et al.
Gene
. 2023 Dec;
898:148110.
PMID: 38151177
The treatment of osteosarcoma patients exhibits individual variability, underscoring the critical importance of targeted therapy. Although (Solute carrier family 35 member A2) SLC35A2's role in the progression of various cancers...
3.
Yin J, Zhou Y, Ding X, Gong R, Zhou Y, Hu H, et al.
Curr Cancer Drug Targets
. 2023 Apr;
24(2):204-219.
PMID: 37076962
Background: Natural killer cells play important roles in tumor immune surveillance, and cancer cells must resist this surveillance in order to progress and metastasise. Introduction: The study aimed to explore...
4.
Li J, Yuan X, Ma C, Li J, Qu G, Yu B, et al.
Front Oncol
. 2023 Apr;
13:1139588.
PMID: 37035213
Objective: Recent knowledge concerning the significance of long non-coding RNA (lncRNA)-mediated ceRNA networks provides new insight into their possible roles as specific biomarkers for the treatment of osteosarcoma (OS). Thus,...
5.
Zeng D, Li J, Yuan X, Cai F, Yu B, Liu L, et al.
Aging (Albany NY)
. 2023 Apr;
15(7):2450-2459.
PMID: 37014329
Background: Osteosarcoma has become the most common bone malignancy in adolescents. Although the clinical treatment of osteosarcoma has advanced considerably in recent years, the 5-year survival rate has not improved...
6.
Zhang F, Sun J, Tang X, Liang Y, Jiao Q, Yu B, et al.
Cell Death Dis
. 2022 Jul;
13(7):590.
PMID: 35803902
Cytarabine (Ara-C) is the first-line drug for the treatment of acute myelogenous leukemia (AML). However, resistance eventually develops, decreasing the efficacy of Ara-C in AML patients. The expression of SAMHD1,...
7.
Yu B, Liu L, Cai F, Peng Y, Tang X, Zeng D, et al.
Cancer Cell Int
. 2022 Feb;
22(1):64.
PMID: 35135529
Background: Osteosarcoma (OS) is a tumour with a high malignancy level and a poor prognosis. First-line chemotherapy for OS has not been improved for many decades. Bromodomain and extraterminal domain...
8.
Sun J, Qian X, Zhang F, Tang X, Ju C, Liu R, et al.
Transl Cancer Res
. 2022 Feb;
8(8):2759-2768.
PMID: 35117033
Background: WT161 is a recently discovered histone deacetylase 6 (HDAC6) inhibitor which shows anti-tumor effects on multiple myelomas and breast cancer. However, the role of WT161 in retinoblastoma remains unclear....
9.
10.
Lv B, Gao G, Guo Y, Zhang Z, Liu R, Dai Z, et al.
Aging (Albany NY)
. 2021 Sep;
13(17):21142-21154.
PMID: 34493692
Background: Osteosarcoma (OS) is a common disease in the world, and its pathogenesis is still unclear. This study aims to identify the key genes that promote the proliferation, invasion, and...